Myriad's Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients

Myriad Genetics, Inc.

announced today that a presentation entitled "Use of a Proliferation-Based mRNA Signature to Predict Outcome in Early-Stage Non-Small Cell Lung Adenocarcinoma," was presented on Sunday, June 3, 2012 at the American Society of Clinical Oncology® (ASCO) Annual Meeting in Chicago. The study demonstrates that the Company's lung cancer prognosis test significantly predicts cancer-specific death in early stage adenocarcinoma lung cancer patients. Researchers at M.D. Anderson Cancer Center, European Institute of Oncology, and Myriad Genetics generated a cell cycle progression (CCP) score from formalin-fixed surgery samples, taken from 381 patients, with stage I and II lung adenocarcinoma. The CCP score was determined to be the most significant predictor of patient outcomes (p=0.007) and significantly additive to clinical variables which included age, stage of disease, gender, smoking status, tumor size and treatment. Additionally, researchers found that the CCP score effectively stratified patient five year survival. Only 8% of patients with a low CCP score succumbed to the disease; however, more than three times as many patients with a high CCP score died from disease.